Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma

The French Public Health Council recommended pneumococcal vaccination combined strategy for all immunocompromised patients in 2012. This strategy consisted in conjugated 13-valent pneumococcal (PCV13) injection followed 2 months later by polysaccharide 23-valent (PPV23) vaccine injection. In 2024, Health authorities changed guidelines to recommend one injection of PREVENAR20 instead of the 2-vaccine scheme general practitioners are usually in charge of this vaccination. Conjugated pneumococcal vaccine enhances the immunogenicity of the polysaccharide vaccine. Acute leukemia and lymphoma are tr

Trial Details

NCT ID
NCT04460235
Phase
PHASE4
Sponsor
Poitiers University Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Prevenar 13 + Pneumovax 23
  • PREVENAR20
Locations (sample)
  • Angers, France|47.47156,-0.55202
  • Bordeaux, France|44.84124,-0.58046
  • Limoges, France|45.83362,1.24759
  • Nantes, France|47.21725,-1.55336
  • Périgueux, France|45.18691,0.71439

Key Eligibility Criteria

  • Patient ≥ 18 year-old.
  • AND medical follow-up in hematology unit
  • AND had received a first course of chemotherapy for diffuse large B cell lymphoma or for follicular lymphoma
  • Life expectancy \> 6 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →